Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.
Angitia Biopharmaceuticals has raised $130.0M across 1 funding round.
Angitia Biopharmaceuticals has raised $130.0M in total across 1 funding round.
Angitia Biopharmaceuticals has raised $130.0M in total across 1 funding round.
Angitia Biopharmaceuticals's investors include Frazier Life Sciences, Venrock Healthcare Capital Partners, 3H Health Investment, Ascenta Capital, Bain Capital Life Sciences, Biotechnology Value Fund, BlackRock, Elikon Venture, Hillhouse Investment, Janus Henderson Investors, Legend Capital, Logos Capital.
Angitia Biopharmaceuticals has raised $130.0M across 1 funding round. Most recently, it raised $130.0M Series D in February 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 5, 2026 | $130.0M Series D | Frazier Life Sciences, Venrock Healthcare Capital Partners | 3H Health Investment, Ascenta Capital, Bain Capital Life Sciences, Biotechnology Value Fund, BlackRock, Elikon Venture, Hillhouse Investment, Janus Henderson Investors, Legend Capital, Logos Capital, Morningside, OrbiMed, RA Capital Management, TF Capital, Wellington Management, Yonghua Capital |